重性抑郁障碍患者纹状体多巴胺转运体结合降低的活体PET与尸检证据
该横断面PET研究用高选择性DAT示踪剂[11C]altropane比较25例未服药重性抑郁障碍(MDD)患者与23名健康对照,发现患者双侧壳核和腹侧被盖区DAT可用性显著降低,且随抑郁发作次数加重;尸检也重复了壳核DAT降低。
要点
- 未服药MDD患者双侧壳核和腹侧被盖区DAT可用性较健康对照显著降低。
- DAT降低随抑郁发作次数增加而加重,且MDD组缺乏健康对照中的年龄相关纹状体DAT下降。
- 腹侧被盖区DAT在感到陷入应激处境的MDD患者中最低,尸检重复壳核DAT降低。
核心结论
- 重性抑郁障碍尤其反复发作者以纹状体DAT表达降低为特征,可能反映中脑边缘通路多巴胺信号低下的代偿性下调。
研究设计与样本
- 横断面PET研究在McLean医院和麻省总医院纳入25例当前未服药MDD患者和23名人口学匹配健康对照,并于Douglas-Bell Canada脑库进行15例抑郁者和14名健康对照的尸检分析。
主要发现
- 与23名健康对照相比,25例MDD患者双侧壳核和腹侧被盖区活体DAT可用性显著降低(Cohen d范围-0.62至-0.71)。
- DAT降低随抑郁发作次数增加而加重,且MDD组未显示健康对照中的年龄相关纹状体DAT下降。
- 腹侧被盖区DAT在报告感到陷入应激处境的MDD患者中最低。
- 尸检分析重复了MDD患者壳核DAT和酪氨酸羟化酶水平较健康对照降低(Cohen d范围-0.92至-1.15)。
临床怎么用
- 对反复发作的MDD患者,可关注纹状体DAT降低所提示的多巴胺通路异常,但尚不能据此常规开展DAT PET诊断。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Major depressive disorder (MDD) might involve dopamine (DA) reductions. The DA transporter (DAT) regulates DA clearance and neurotransmission and is sensitive to DA levels, with preclinical studies (including those involving inescapable stressors) showing that DAT density decreases when DA signaling is reduced. Despite preclinical data, evidence of reduced DAT in MDD is inconclusive. OBJECTIVE: Using a highly selective DAT positron emission tomography (PET) tracer ([11C] altropane), DAT availability was probed in individuals with MDD who were not taking medication. Levels of DAT expression were also evaluated in postmortem tissues from donors with MDD who died by suicide. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional PET study was conducted at McLean Hospital (Belmont, Massachusetts) and Massachusetts General Hospital (Boston) and enrolled consecutive individuals with MDD who were not taking medication and demographically matched healthy controls between January 2012 and March 2014. Brain tissues were obtained from the Douglas-Bell Canada Brain Bank. For the PET component, 25 individuals with current MDD who were not taking medication and 23 healthy controls recruited from McLean Hospital were included (all provided usable data). For the postmortem component, 15 individuals with depression and 14 healthy controls were considered. INTERVENTION: PET scan. MAIN OUTCOMES AND MEASURES: Striatal and midbrain DAT binding potential was assessed. For the postmortem component, tyrosine hydroxylase and DAT levels were evaluated using Western blots. RESULTS: Compared with 23 healthy controls (13 women [56.5%]; mean [SD] age, 26.49 [7.26] years), 25 individuals with MDD (19 women [76.0%]; mean [SD] age, 26.52 [5.92] years) showed significantly lower in vivo DAT availability in the bilateral putamen and ventral tegmental area (Cohen d range, -0.62 to -0.71), and both reductions were exacerbated with increasing numbers of depressive episodes. Unlike healthy controls, the MDD group failed to show an age-associated reduction in striatal DAT availability, with young individuals with MDD being indistinguishable from older healthy controls. Moreover, DAT availability in the ventral tegmental area was lowest in individuals with MDD who reported feeling trapped in stressful circumstances. Lower DAT levels (and tyrosine hydroxylase) in the putamen of MDD compared with healthy controls were replicated in postmortem analyses (Cohen d range, -0.92 to -1.15). CONCLUSIONS AND RELEVANCE: Major depressive disorder, particularly with recurring episodes, is characterized by decreased striatal DAT expression, which might reflect a compensatory downregulation due to low DA signaling within mesolimbic pathways.
引用
- Pizzagalli DA, Berretta S, Wooten D, et al. Assessment of Striatal Dopamine Transporter Binding in Individuals With Major Depressive Disorder: In Vivo Positron Emission Tomography and Postmortem Evidence. JAMA Psychiatry. 2019. PMID: 31042280. doi:10.1001/jamapsychiatry.2019.0801
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。